| Source: |
| Type: |
| Tumor cell migration is a critical process in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant sites in the body. |
| Colorectal cancer is a broader term that encompasses both colon and rectal cancer. |
| 172- | Api, | Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/β-catenin signaling pathway |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | HTC15 |
| 174- | Api, | Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | DLD1 |
| 5398- | Ash, | Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90/HIF-1α/EMT axis |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 1179- | Ash, | Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity |
| - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 2678- | BBR, | Berberine as a Potential Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 2682- | BBR, | Berberine Inhibited Growth and Migration of Human Colon Cancer Cell Lines by Increasing Phosphatase and Tensin and Inhibiting Aquaporins 1, 3 and 5 Expressions |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | HCT116 |
| 2719- | BetA, | Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Bladder, | UMUC3 | - | in-vitro, | Bladder, | 5637 |
| 5476- | BM, | In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with Ca2+ Flux and Loss of Plasma Membrane Integrity |
| - | vitro+vivo, | CRC, | HT29 |
| 2047- | Buty, | Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Nor, | SV-HUC-1 | - | in-vitro, | Bladder, | 5637 | - | in-vivo, | NA, | NA |
| 5868- | CA, | Carnosic acid inhibits the proliferation and migration capacity of human colorectal cancer cells |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Colon, | HT29 | - | in-vitro, | CRC, | LoVo |
| 1517- | CAP, | Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1) |
| - | in-vitro, | Bladder, | TSGH8301 | - | in-vitro, | CRC, | T24/HTB-9 |
| 6179- | Cro, | Crocetin suppresses the growth and migration in HCT-116 human colorectal cancer cells by activating the p-38 MAPK signaling pathway |
| - | NA, | CRC, | HCT116 |
| 2974- | CUR, | Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT15 | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | SW-620 | - | in-vivo, | NA, | NA |
| 405- | CUR, | 5-FU, | Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis |
| - | vitro+vivo, | CRC, | HCT116 |
| 447- | CUR, | OXA, | Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway |
| - | vitro+vivo, | CRC, | HCT116 |
| 450- | CUR, | Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44 |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT8 |
| - | in-vitro, | CRC, | SW480 |
| 830- | GAR, | Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 1116- | GI, | 6-Shogaol Inhibits the Cell Migration of Colon Cancer by Suppressing the EMT Process Through the IKKβ/NF-κB/Snail Pathway |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | CRC, | HCT116 |
| 858- | Gra, | Annona muricata leaves induce G₁ cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 |
| 4531- | MAG, | Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway |
| - | in-vitro, | CRC, | HCT116 |
| 4926- | PEITC, | PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT |
| - | in-vitro, | CRC, | SW48 |
| 5211- | PI, | Piperine inhibits colorectal cancer migration and invasion by regulating STAT3/Snail-mediated epithelial-mesenchymal transition |
| - | in-vitro, | CRC, | NA |
| 1016- | PI, | Piperine suppresses the Wnt/β-catenin pathway and has anti-cancer effects on colorectal cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | DLD1 |
| 2945- | PL, | Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 5164- | PLB, | Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2 |
| - | vitro+vivo, | CRC, | NA | - | in-vitro, | Pca, | NA |
| - | in-vivo, | CRC, | Caco-2 | - | vitro+vivo, | CRC, | CX-1 |
| 5017- | UA, | Ursolic acid disturbs ROS homeostasis and regulates survival-associated gene expression to induce apoptosis in intestinal cancer cells |
| - | in-vitro, | Cerv, | INT-407 | - | in-vitro, | CRC, | HCT116 |
| 4847- | Uro, | Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells |
| - | in-vitro, | CRC, | SW-620 |
| 1820- | VitK3, | Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:6 Cells:% prod#:% Target#:326 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid